Replies to post #17094 on Health Discovery Corp (HDVY)

[LocWolf]

Somewhat of a great question but believe once NeoGenomic Corporation with and around Dr. Albitar they were able to see just what HDC had within their technology and (may have) designed a parallel application without using our technology directly...but really I have "no real clue".

My thoughts on Intel and the prostate test? Who knows and I'm sure in their medical technologies something exists but prove it? So I ask myself where is the gravy located that can benefit my company (HDC) the most in thoughts of Custer's last stand or the Alamo.

Intel make mega mathematics within the huge Chip and memory markets and have possibly licensed goods with 3-4 technological patents. Intel also is easily seen as abusing HDC in much of the documentations since the beginning of time.

In terms of damages by Intel I said I would never ever place figures in a thread since danger of lawsuit/threats that go back to 1999 under a different alias but if we are successful in court and triple damages are assessed a range of .55 - 1.00 per share is possible or should I say I believe.

The only thing as to a win and we never had any direct product, product damages so what bearing will that have???

[Zenos Arrow]

From what I remember, the first shot at our lab-developed-test for prostate cancer was with Clarient/GE. We went through a successful clinical trials process, but Clarient did not have the money to hire a separate sales force to call on urologists. Clarient was an anatomical pathology lab (tissue testing), and their current team was trained to sell to pathologists. Our collective disappointment was short-lived because we (at least) had some good clinical trial data.

Next up was Quest Diagnostics and Abbott. HDC & Quest Dx completed the clinical trial as laid out in their licensing agreement. HDC’s 4-gene urine PSA showed a significant improvement on the current (not very sensitive/accurate) PSA. Shareholders started doing the math; 25 mil PSAs ordered in the US = 2.5-5 billion in yearly revenue. In tandem, Abbott was developing the test kits - Quest the actual testing. I remember Quest Dx wanted more phase 3 data, which meant enrolling more patients.

For some reason, HDC did not want to do that and took their ball and went home to NeoGenomics – whom we had a licensing agreement and ended up suing them. This was not for the PSA though, but cancer diagnostics for tissue (which HDC developed years prior).

So again, we had some great “at-bats,” and companies benefited from these licensing agreements. Just not the shareholders. Which is why our present situation seems like the undertow of cosmic justice, kismet or karma.